carbenoxolone sodium has been researched along with Diabetes Mellitus, Type 2 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fotsch, C; Wang, M | 1 |
| Dhanesha, N; Dhote, V; Jain, M; Joharapurkar, A; Kshirsagar, S; Shah, G; Sharma, A | 1 |
| Andrews, RC; Rooyackers, O; Walker, BR | 1 |
| Abdallah, BM; Beck-Nielsen, H; Gaster, M | 1 |
| Davani, B; Efendic, S; Hult, M; Jörnvall, H; Khan, A; Mårtensson, E; Okret, S; Oppermann, UC | 1 |
1 trial(s) available for carbenoxolone sodium and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Blood Glucose; Blood Pressure; Carbenoxolone; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Electrolytes; Enzyme Inhibitors; Humans; Hydroxysteroid Dehydrogenases; Insulin Resistance; Kinetics; Lipids; Male; Middle Aged | 2003 |
4 other study(ies) available for carbenoxolone sodium and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Blockade of glucocorticoid excess at the tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Carbenoxolone; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucocorticoids; Glycyrrhetinic Acid; Humans; Insulin Resistance; Obesity | 2008 |
Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adiposity; Animals; Anti-Obesity Agents; Brain; Carbenoxolone; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Energy Metabolism; Enzyme Inhibitors; Female; Glucose-6-Phosphatase; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Mice; Mice, Mutant Strains; Obesity; Pancreas; Phosphoenolpyruvate Carboxykinase (ATP) | 2012 |
Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 11-beta-Hydroxysteroid Dehydrogenase Type 2; Carbenoxolone; Cortisone; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hydrocortisone; Insulin Resistance; Liver X Receptors; Middle Aged; Muscle Fibers, Skeletal; Obesity; Orphan Nuclear Receptors; Receptors, Cytoplasmic and Nuclear; Receptors, Glucocorticoid | 2005 |
Type 1 11beta -hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Anti-Ulcer Agents; Carbenoxolone; Corticosterone; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Genes, Reporter; Glucocorticoids; Glucose; Humans; Hydroxysteroid Dehydrogenases; Insulin; Islets of Langerhans; Isoenzymes; Kinetics; Ligands; Mice; Mice, Knockout; Mice, Mutant Strains; Pancreas; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tissue Distribution; Transcription, Genetic | 2000 |